泰坦製藥 TTNP 深 滬
等待開盤 08-07 09:30:00 美东时间
3.93
+0.010
+0.26%
華盛通- 最 高3.93
- 今 開3.8019
- 成交量 5292股
- 最 低 3.8019
- 昨 收 3.92
- 總市值 522.77万
- 52周最高 14.80
- 市盈率 靜 --
- 換手率 0.40%
- 52周最低 3.03
- 委 比 -69.23%
- 總股本 133.02万
- 歷史最高 36000.00
- 量 比 0.41
- 振 幅 3.27%
- 歷史最低 3.03
- 每 手 1
- 風險率 1.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Titan Pharmaceuticals Announces Merger with Black Titan
New activity is brewing for Titan Pharmaceuticals ( ($TTNP) ). The company has ...
07-23 05:33
Titan Pharmaceuticals Completes Securities Purchase Agreement
Titan Pharmaceuticals ( ($TTNP) ) just unveiled an update. On June 24, 2025, Ti...
06-28 04:59
Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock
Titan Pharmaceuticals announced the completion of a private placement of 60,000 shares of its Series C Convertible Preferred Stock to Blue Harbour Asset Management for $600,000 at a conversion price of $3.40. The transaction includes a beneficial ownership blocker limiting Blue Harbour to a maximum of 19.99% of the Company's outstanding common stock. The shares were sold under Regulation S and are subject to a registration rights agreement. Addit...
06-27 20:05
Titan Pharmaceuticals Announces Filing By Black Titan Corporation With SEC For Previously Announced Proposed Combination Of Titan And TalenTec
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission ("SEC") of a registration statement on Form F-4
06-03 20:49
Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.
Titan Pharmaceuticals and TalenTec have entered into a Merger Agreement for a "reverse merger" transaction. Black Titan Corporation filed a Form F-4 with the SEC, including a preliminary proxy statement, in connection with the proposed combination. The transaction requires approval from Titan's stockholders and is expected to close in the third quarter of 2025, subject to customary closing conditions. Investors are advised to review the prelimina...
06-03 12:45
Titan Pharmaceuticals announces $1 million private placement
Titan Pharmaceuticals (NASDAQ:TTNP) announced on Friday that it has completed a private placement of the company’s newly designated Series B convertible preferred stock with Blue Harbour Asset Managem...
04-12 04:41
快讯 | 更正 - 泰坦制药公司 - 1月3日，收到纳斯达克违规通知（添加已删除日期 '3'）
Corrected-Titan Pharmaceuticals Inc - on Jan 3, Receives Nasdaq Noncompliance N...
01-09 06:13
Titan Pharmaceuticals Appoints Chay Weei Jye as CEO
Titan Pharmaceuticals ( ($TTNP) ) has issued an announcement. Chay Weei Jye has...
2024-12-07 05:58
Titan Pharmaceuticals announces non-compliance notice from Nasdaq
Titan Pharmaceuticals (NASDAQ:TTNP) was notified by Nasdaq that it failed to file its Q3 report on time, violating listing requirements. The company has until January 21, 2025, to submit a plan to reg...
2024-11-28 05:22
Titan Pharmaceuticals Gets Non-Compliance Notice From Nasdaq
Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to regain compliance with the Listing Rule.
2024-11-28 05:08
